News / New publications

Research

We work together for a better translational approach, from basic to clinical science

  • Read more

Core facilities

Our advanced core facilities offer excellent opportunities

  • Read more

Recruitment

We welcome the best research talents from Norway and the rest of the world

  • Read more

Archives IEMR

  • Publications
  • News archive

About IEMR

  • About
  • Scientific strategy
  • Staff
  • Collaborations
  • Funding
  • Visual profile

Contact IEMR

  • Contact
  • Group leaders
  • Leadership
  • Safety representative (VO)
  • Subscribe to newsletter

Sacubitril/valsartan prevents myocardial remodeling during pressure overload

Nordén ES, Bendiksen BA, Andresen H, Bergo KK, Espe EK, Hasic A, Hauge-Iversen IM, Veras I, Hussain RI, Sjaastad I, Christensen G, Cataliotti A

Sacubitril/valsartan ameliorates cardiac hypertrophy and preserves diastolic function in cardiac pressure overload

—

 

Remodeling of the heart due to pressure overload is a significant contributor to cardiac disease worldwide, impacting cardiac function through a multitude of harmful changes. Different drugs are employed in treatment of this condition, and in the current article we investigate the effects of a new drug, Sacubitril/Valsartan, comparing it to an established therapeutic modality. We found that Sacubitril/Valsartan prevents several of the deleterious changes, affecting both growth of cardiac cells and the ability of the heart to relax. The treatment did however not improve changes in contractile function of the heart, highlighting the need for further therapeutic developments. 

ESC Heart Fail, 8 (2), 918-927
PubMed 33497525 DOI 10.1002/ehf2.13177

Einar Sjaastad Nordén

Doctoral Research Fellow

  • View profile

Alessandro Cataliotti

Group Leader & Professor

  • View profile

Institute for Experimental Medical Research

Oslo University Hospital, Ullevål

PB 4956 Nydalen

NO-0424 Oslo

Norway

  • Research
  • Core facilities
  • Recruitment
  • Publications
  • News archive
  • About
  • Scientific strategy
  • Staff
  • Collaborations
  • Funding
  • Visual profile
  • Contact
  • Group leaders
  • Leadership
  • Safety representative (VO)
  • Subscribe to newsletter